Commission Implementing Regulation (EU) 2026/372 of 20 February 2026 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances 1-decanol, 1-naphthylacetamide, 1-naphthylacetic acid, 6-benzyladenine, aluminium sulfate, boscalid, dodine, esfenvalerate, eugenol, fenpyroximate, fluazifop-P, fluazinam, fluometuron, fluopyram, flutolanil, geraniol, malathion, penoxsulam, pinoxaden, prohexadione, proquinazid, prosulfuron, pyrethrins, pyridaben, pyrimethanil, sintofen, spiroxamine, sulphur and thymol

• CELEX: Implementing Regulation (EU) 2026/372
• Articles: 3

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Schedules & Appendices

ANNEX

ANNEX

1.

Part A of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 135, Pyrimethanil, the date is replaced by ‘30 June 2027’;

(2)

in the sixth column, expiration of approval, of row 164, Boscalid, the date is replaced by ‘31 March 2028’;

(3)

in the sixth column, expiration of approval, of row 187, Flutolanil, the date is replaced by ‘15 June 2027’;

(4)

in the sixth column, expiration of approval, of row 189, Fluazinam, the date is replaced by ‘30 November 2027’;

(5)

in the sixth column, expiration of approval, of row 213, Fenpyroximate, the date is replaced by ‘31 January 2028’;

(6)

in the sixth column, expiration of approval, of row 246, Pyrethrins, the date is replaced by ‘30 April 2028’;

(7)

in the sixth column, expiration of approval, of row 292, Sulphur, the date is replaced by ‘31 July 2027’;

(8)

in the sixth column, expiration of approval, of row 300, Malathion, the date is replaced by ‘15 July 2028’;

(9)

in the sixth column, expiration of approval, of row 301, Penoxsulam, the date is replaced by ‘15 May 2027’;

(10)

in the sixth column, expiration of approval, of row 302, Proquinazid, the date is replaced by ‘31 December 2027’;

(11)

in the sixth column, expiration of approval, of row 313, Pyridaben, the date is replaced by ‘31 January 2030’;

(12)

in the sixth column, expiration of approval, of row 317, 6-benzyladenine, the date is replaced by ‘15 January 2030’;

(13)

in the sixth column, expiration of approval, of row 323, Dodine, the date is replaced by ‘30 June 2028’;

(14)

in the sixth column, expiration of approval, of row 333, 1-decanol, the date is replaced by ‘30 June 2028’;

(15)

in the sixth column, expiration of approval, of row 335, Fluometuron, the date is replaced by ‘15 January 2030’;

(16)

in the sixth column, expiration of approval, of row 341, Sintofen, the date is replaced by ‘15 January 2030’;

(17)

in the sixth column, expiration of approval, of row 346, Aluminium sulfate, the date is replaced by ‘15 January 2030’.

2.

Part B of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 6, Prohexadione, the date is replaced by ‘15 May 2028’;

(2)

in the sixth column, expiration of approval, of row 7, Spiroxamine, the date is replaced by ‘30 November 2029’;

(3)

in the sixth column, expiration of approval, of row 12, 1-naphthylacetamide, the date is replaced by ‘30 November 2029’;

(4)

in the sixth column, expiration of approval, of row 13, 1-naphthylacetic acid, the date is replaced by ‘30 November 2029’;

(5)

in the sixth column, expiration of approval, of row 15, Fluazifop-P, the date is replaced by ‘30 November 2029’;

(6)

in the sixth column, expiration of approval, of row 45, Eugenol, the date is replaced by ‘15 April 2028’;

(7)

in the sixth column, expiration of approval, of row 46, Geraniol, the date is replaced by ‘15 April 2028’;

(8)

in the sixth column, expiration of approval, of row 47, Thymol, the date is replaced by ‘15 April 2028’;

(9)

in the sixth column, expiration of approval, of row 51, Fluopyram, the date is replaced by ‘15 June 2028’;

(10)

in the sixth column, expiration of approval, of row 97, Pinoxaden, the date is replaced by ‘31 December 2029’.

3.

Part E of the Annex to Implementing Regulation (EU) No 540/2011 is amended as follows:

(1)

in the sixth column, expiration of approval, of row 2, Esfenvalerate, the date is replaced by ‘30 November 2029’;

(2)

in the sixth column, expiration of approval, of row 6, Prosulfuron, the date is replaced by ‘15 December 2029’.